Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
This is a long-term observational study of patients that were treated with at least 1 dose of
 study treatment (plerixafor or placebo) in the AMD3100-3102 protocol (NCT00103662).
This is a long-term observational study of patients who received at least one dose of study
 treatment (plerixafor or placebo) in a multicenter, randomized, double blind,
 placebo-controlled study to evaluate AMD3100 plus granulocyte colony stimulating factor
 (GCSF) versus G-CSF plus placebo to mobilize and transplant Multiple Myeloma (MM) patients
 (protocol AMD31003102LTF [NCT00103662]). The objective of this study is to assess
 progression-free survival and overall survival of patients treated with at least 1 dose of
 study treatment (placebo or plerixafor) for a period of 5 years following the first dose of
 study treatment (placebo or plerixafor) in protocol AMD3100-3102 (NCT00103662).
Inclusion Criteria:

 -  All patients who received a dose of study treatment (plerixafor or placebo) in
 protocol AMD3100-3102 (NCT00103662)

 Exclusion Criteria:

 -  No Exclusion Criteria